SCHEMBL20164443

SCHEMBL20164443

CCCNc1nc(NC)nc2c(NCCO)nc(NC)nc12

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 8/20 0.66
KMT2A Q03164 2/20 0.37
MAPK1 P28482 2/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
FLT3 P36888 2/20 0.36
TYRO3 Q06418 1/20 0.36
MERTK Q12866 1/20 0.36
GAS6 Q14393 1/20 0.36
CDK1 P06493 2/20 0.35
TLR7 Q9NYK1 1/20 0.34
APP P05067 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164696 0.98 SLC29A1 (0.64) SLC29A1KMT2AMAPK1POLBKDM4E
SCHEMBL16094829 0.97 SLC29A1 (0.71) SLC29A1KMT2AMAPK1POLBKDM4E
SCHEMBL18360938 0.91 SLC29A1 (0.56) SLC29A1TLR7APP
SCHEMBL16094312 0.91 SLC29A1 (0.51) SLC29A1KMT2AMEN1MERTKTLR7
SCHEMBL20164523 0.90 SLC29A1 (0.62) SLC29A1KMT2AFLT3TYRO3MERTK
SCHEMBL20164763 0.89 SLC29A1 (0.60) SLC29A1KMT2AMAPK1POLBKDM4E
Hydrochloric Acid SCHEMBL17494536 0.89 SLC29A1 (0.50) SLC29A1KMT2AMEN1MERTKTLR7
Hydrochloric Acid SCHEMBL20164421 0.89 SLC29A1 (0.60) SLC29A1KMT2AFLT3TYRO3MERTK
Hydrochloric Acid SCHEMBL20164519 0.88 SLC29A1 (0.58) SLC29A1KMT2AMAPK1POLBKDM4E
SCHEMBL20179388 0.86 SLC29A1 (0.66) SLC29A1KMT2AMAPK1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US claimed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885KMT2A 2456/4885MAPK1 4681/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885KMT2A 1865/4885MAPK1 3271/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885KMT2A 2528/4885MAPK1 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.